Skip to main content Help with accessibility Skip to main navigation

Position Statements

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - January - 2019
BNF chapter: Central nervous system

This guidance does not apply to the use of Sativex® (delta-9-etrahydrocannabinol and cannabidiol) oromucosal spray as an adjunct treatment for moderate to severe spasticity in multiple sclerosis.

**This Guideline is currently under review. For further information please click here**
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Pending
Date Posted: 19 - July - 2022
BNF chapter: Central nervous system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2016
BNF chapter: Central nervous system

The Lancashire Medicines Management Group does not recommend the prescribing of e-Cigarettes

Not adopted
Adopted
Pending
Not adopted
Adopted
Pending
Adopted
Pending
Date Posted: 14 - September - 2022
BNF chapter: Central nervous system

To be read in conjunction with the LSCMMG guideline ‘Assessing suitability of strong opioid use’

 

Not adopted
Not adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - July - 2018
BNF chapter: Central nervous system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted

Prescribing request from out-of-area specialists to Lancashire GPs where there is an inconsistency with the recommended local and out-of-area colour classification

**This Guideline is currently under review. For further information please click here**
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Adopted
Not adopted
Date Posted: 01 - September - 2016
BNF chapter: Central nervous system

This position statement relates to the use of tapentadol MR for the following indications:

1. As a treatment option for intractable neuropathic pain in non-palliative care patients
2. As a treatment for nonspecific pain